Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
A multi-OS attack can turn one threat into several different investigations at once. The campaign may follow a different path ...
A severe Android intent‑redirection vulnerability in a widely deployed SDK exposed sensitive user data across millions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results